Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436527 · ClinicalTrials.gov registry record · Phase 4
Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT00436527 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 26 participants.
The verdict
NCT00436527, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.
Interventions
- DRUG Metronidazole gel 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-08 |
| Est. Completion | 2006-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436527
The ClinicalTrials.gov registry entry for NCT00436527 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metronidazole gel 1% is the first listed.
NCT00436527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00436527 about?
NCT00436527 is a clinical study titled "Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application". This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.
What is the current status of trial NCT00436527?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2006-08. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00436527?
The interventions under investigation include: Metronidazole gel 1% (DRUG).
Who is sponsoring clinical trial NCT00436527?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.